Immuneering Stock (NASDAQ:IMRX)


ForecastOwnershipFinancialsChart

Previous Close

$2.04

52W Range

$1.00 - $8.89

50D Avg

$2.18

200D Avg

$2.34

Market Cap

$63.34M

Avg Vol (3M)

$5.61M

Beta

-0.40

Div Yield

-

IMRX Company Profile


Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

66

IPO Date

Jul 30, 2021

Website

IMRX Performance


IMRX Financial Summary


Dec 23Dec 22Dec 21
Revenue-$316.95K$2.08M
Operating Income$-58.41B$-51.74M$-33.89M
Net Income$-53.47B$-49.28M$-33.54M
EBITDA$-58.41B$-51.71M$-33.89M
Basic EPS$-1.88$-1.87$-2.46
Diluted EPS$-1.88$-1.87$-2.46

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q4 22Mar 06, 23 | 10:50 PM

Peer Comparison


TickerCompany
PMVPPMV Pharmaceuticals, Inc.
GOSSGossamer Bio, Inc.
CGEMCullinan Oncology, Inc.
IVAInventiva S.A.
CNTACentessa Pharmaceuticals plc
IKNAIkena Oncology, Inc.
LRMRLarimar Therapeutics, Inc.
REPLReplimune Group, Inc.
KRONKronos Bio, Inc.
GLUEMonte Rosa Therapeutics, Inc.
NAMSNewAmsterdam Pharma Company N.V.
LYRALyra Therapeutics, Inc.
CELCCelcuity Inc.
NVCTNuvectis Pharma, Inc.
ELVNEnliven Therapeutics, Inc.
CMPXCompass Therapeutics, Inc.